Its handheld and benchtop devices read strands of native DNA and RNA in real time, streaming data as molecules pass through protein pores, and the technology has travelled from Antarctic ice to the International Space Station. But for public-market investors, the story is now less about scientific novelty and more about commercial discipline: after £223.9m of FY2025 revenue and a new CEO with a diagnostics background, the question is whether growth can turn into sustained profit.
The Quick Version
- FY2025 revenue reached £223.9m, up 22.2% reported (24.2% constant currency), slightly ahead of guidance.
- Gross margin rose to 58.6% and the adjusted EBITDA loss narrowed to £86.7m; management targets adjusted EBITDA breakeven in FY2027 and cash-flow positivity in FY2028.
- Cash, equivalents and liquid investments stood at about £302.8m at 31 December 2025, down from £403.8m a year earlier.
- Francis Van Parys became CEO on 2 March 2026, succeeding co-founder Gordon Sanghera, who moved to an advisory role.
- The company is pursuing patent and trade-secret litigation against MGI Tech; in Australia MGI has conceded infringement of four patents, with a trial on remaining issues set for 2027.
What Oxford Nanopore Actually Sells
It designs, manufactures and sells DNA and RNA sequencing platforms — the portable MinION, benchtop GridION and high-throughput PromethION — plus the consumable flow cells, reagent kits and software that generate recurring revenue from the installed base. Spun out of the University of Oxford in 2005, it floated on the LSE Main Market on 30 September 2021 at 425p, raising roughly £350m in one of London's largest life-sciences listings, under ticker ONT.
Reading Molecules in Real Time
Nanopore sequencing passes a single strand of DNA or RNA through a protein nanopore, measuring the electrical disruption as it threads through and translating it into a sequence — with the crucial 'real-time' quality that data can be read while sequencing is still under way. The approach produces long reads (helping resolve complex genome regions), reads native molecules directly (detecting chemical modifications like methylation without separate assays), and can sequence both DNA and RNA.
The Mix Shift: From Handheld to High-Throughput
PromethION-linked revenue rose roughly 43% year-on-year in FY2025, while MinION-related revenue was broadly flat — signalling a shift toward larger, higher-consumption laboratory customers, encouraging for recurring revenue but tempering the earlier narrative of ubiquitous handheld adoption. Growth was led by clinical customers (up around 60% reported), followed by biopharma and applied-industrial demand, while research — historically the largest end-market — grew a more modest 15%.
The Numbers and the Roadmap to Profit
Gross margin rose 110 basis points to 58.6% (adjusted 59.4%), and the adjusted EBITDA loss narrowed to £86.7m from £117.9m. The reported loss was broadly stable at £145.2m. Cash, equivalents and liquid investments stood at approximately £302.8m at 31 December 2025, down from £403.8m twelve months before.
Management targets adjusted EBITDA breakeven in FY2027 and cash-flow positivity in FY2028. For FY2026 it guides to constant-currency revenue growth of 21-25%, gross margin around 62%, and operating-cost growth held to 0-5% — the mechanism by which losses are meant to close.
New Leadership, New Partnerships
Francis Van Parys became CEO on 2 March 2026, succeeding co-founder Gordon Sanghera after roughly two decades, with a background in diagnostics signalling clinical and applied markets as central to the next phase. In April 2026 the company announced an expanded second-phase collaboration with Cepheid (Danaher) combining GeneXpert with nanopore sequencing for infectious-disease workflows, with an early-access programme flagged for later in 2026.
The MGI Litigation
Oxford Nanopore is pursuing patent and trade-secret litigation against MGI Tech and affiliated entities. In the Federal Court of Australia, MGI has conceded that its Cyclone SEQ WT02 product infringes four Australian patents, with the judge noting liability isn't in dispute; a trial addressing MGI's remaining defences and any additional or enhanced damages is scheduled for 2027. A separate action in the English High Court alleges misappropriation of trade secrets and breach of confidence and contract. Outcomes remain uncertain.
Risks Worth Weighing
The company isn't yet profitable and depends on continued execution to reach breakeven — any slippage in growth or margins would extend the cash-consumption period. Competition from far larger, well-capitalised rivals (Illumina in short-read, PacBio in long-read, MGI Tech/BGI) is intense. Revenue can be lumpy, with a meaningful share historically tied to larger contracts and government or public-health programmes.
What to Watch Next
Delivery against — or divergence from — FY2026 guidance and the FY2027 breakeven target at each reporting point. Progress in clinical and diagnostics markets, including tangible output from the Cepheid collaboration. Continued gains in sequencing accuracy and throughput documented in peer-reviewed work. Resolution of the MGI litigation.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...